Experts raise questions about severity of Trump's COVID-19On Saturday, the president was started on a five-day course of intravenous antiviral drug remdesivir, which is sold by Gilead Sciences.US President Donald Trump arrives to address a briefing at the White House, August 13, 2020.(photo credit: KEVIN LAMARQUE/REUTERS)
